Key takeaways for Wisconsin
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • BadgerCare Plus / Wisconsin Medicaid coverage rules apply for Prediabetes patients in Wisconsin — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Wisconsin-specific context
Wisconsin has telehealth access concentrated in Milwaukee, Madison, Green Bay metros, with additional reach to Kenosha and Racine. UW Health, Aurora Health Care, Froedtert Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.dhs.wisconsin.gov.
Wisconsintelehealth & pricing rules
- • Wisconsin permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Wisconsin allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Wisconsin: ~$245/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.